Business Overview: MaxCyte, Inc. (Nasdaq: MXCT)

---

Executive Summary

MaxCyte, Inc. is a commercial-stage cell-engineering company built around its proprietary Flow Electroporation technology — a non-viral method for delivering DNA, mRNA, siRNA, and proteins into cells. Incorporated in Delaware in July 1998 (originally as Theramed, Inc.; renamed MaxCyte in 2001) and headquartered in Rockville, Maryland, MaxCyte established an FDA Master File for its platform in 2002 and launched its first commercial instrument in 2003.

MaxCyte matters because its ExPERT platform (instruments DTx, ATx, STx, GTx, and VLx) is embedded directly inside the manufacturing processes of cell-therapy developers — including the program that produced the first FDA-approved ex vivo cell therapy engineered using MaxCyte's technology (approved December 2023) — making the company a foundational, picks-and-shovels supplier to the broader cell and gene therapy industry rather than a therapy developer itself.

---

1. Core Business Model & How They Work

[ Instrument/Consumable Sale ] ➡️ [ Research License ($150K/instrument/yr) ] ➡️ [ Strategic Platform License (SPL) signed with biopharma ] ➡️ [ Pre-commercial Milestone Payments ] ➡️ [ Clinical License ($250K/instrument/yr) ] ➡️ [ Commercial Sales-Based Royalty Payments ]

Revenue comes from five sources: (1) instrument, processing-assembly, and consumable sales to new customers; (2) repeat sales of the same to existing customers; (3) annual instrument license fees paid by cell-therapy customers; (4) pre-commercial milestone payments under Strategic Platform License (SPL) agreements; and (5) commercial sales-based payments once an SPL partner's therapy reaches the market. This "razor-and-blade-plus-royalty" model means MaxCyte earns recurring revenue long before — and increasing revenue after — a partner's drug is approved.

---

2. Product Portfolio

---

3. Competitive Landscape

                     BROAD LIFE-SCIENCE TOOLS  <——————→  CELL-ENGINEERING SPECIALIST
  Large diversified   │ Thermo Fisher Scientific,                        │
  tools companies      │ Bio-Rad Laboratories                             │
                       │                           [ MAXCYTE ]             │
  Mid-size cell/gene    │              Lonza Group, Miltenyi Biotec         │
  therapy tooling       │                                                    │
                       │                                   Harvard Biosciences,│
  Smaller/academic       │                                   academic spinouts │
  spinouts               │                                                    │

Named competitors include Lonza Group AG, Thermo Fisher Scientific, Miltenyi Biotec, Bio-Rad Laboratories, and Harvard Biosciences, alongside smaller companies and academic spinouts. Several of these — particularly Thermo Fisher and Lonza — have vastly greater financial resources and broader life-science-tools portfolios, but none offers an electroporation platform with MaxCyte's regulatory track record (an active FDA Master File since 2002) and installed base.

---

4. Strategic Strengths & Risks

Strengths (The Moat)

• Deep regulatory embedding: MaxCyte's Flow Electroporation platform is frequently cited directly in partners' own FDA filings via the Master File, and the platform was used in the first FDA-approved ex vivo cell therapy (December 2023) — once a drug developer validates its manufacturing process on MaxCyte's instruments, switching platforms mid-program would require re-validating the entire manufacturing process with regulators, an extremely high switching cost.
• Royalty-style upside embedded in SPL contracts: with 31 active SPLs carrying over $2 billion of potential milestones and growing clinical-stage royalty exposure, MaxCyte's economics scale directly with its partners' clinical and commercial success without MaxCyte bearing the R&D or regulatory risk of drug development itself.
• Broad installed base: more than 857 instruments installed globally, including with a majority of the top 25 pharmaceutical companies by 2024 revenue, gives MaxCyte a wide net of potential future SPL conversions.

Risks

• Customer concentration at the program level: much of the pre-commercial milestone value sits in a relatively small number of clinical-stage programs, so a handful of trial failures or discontinuations could materially reduce the eventual royalty pool.
• Persistent net losses: a $44.6 million net loss in 2025 (versus $41.1 million in 2024) and a $261.5 million accumulated deficit show the company is still not self-funding, despite a growing installed base.
• Competitive resource gap: Thermo Fisher and Lonza can out-invest MaxCyte in adjacent delivery technologies (e.g., lipid nanoparticles, viral vectors) that could reduce the addressable market for electroporation specifically.
• Binary dependence on partners' clinical success: MaxCyte's upside is tied to therapies it does not control the development of — a wave of partner trial failures would directly slow SPL-driven revenue growth.

---

5. Financial Overview

---

6. Summary Conclusion

MaxCyte's moat is unusually strong for a life-science tools company of its size: deep regulatory embedding through an FDA Master File, a platform used in the first approved ex vivo cell therapy, and switching costs so high that a drug developer effectively cannot change electroporation platforms mid-program without re-validating its manufacturing process. The trade-off is that MaxCyte's financial success is a leveraged bet on its partners' clinical trial outcomes rather than something fully within its own control, and the company remains unprofitable while that royalty pipeline matures — meaning the moat is real, but the payoff is still mostly ahead of it rather than realized today.